A new brain scan could help detect early signs of Alzheimer’s by spotting a protein linked to memory loss.
It works well in Hispanic and White adults who also have amyloid
buildup, but not in Black adults, highlighting the need for more diverse
studies.
New Brain Imaging Benchmark for Alzheimer’s Risk
Researchers at the Keck School of Medicine of USC have uncovered a new brain
scan marker that could help identify early signs of Alzheimer’s disease. The
discovery comes from the Stevens Neuroimaging and Informatics Institute and is
part of a large national study focused on brain aging and health disparities.
Their work, published in Imaging Neuroscience, could lead to better tools for
detecting Alzheimer’s risk, especially in Hispanic and White adults.
The team used a special type of brain scan called tau
PET, which tracks a protein known as tau that builds up in the brain and
contributes to Alzheimer’s. By studying more than 675 older adults, they
searched for a clear signal — a “cut-point” — that shows when tau levels become
high enough to suggest early memory decline or other symptoms.
Tau PET scans make it possible to see how much tau has
collected in the brain using a safe, low-dose tracer. If tau levels pass a
certain threshold, it may mean the brain is on the path to Alzheimer’s. This
new cut-point could help doctors catch those signs earlier and more accurately.
The research team used the tau PET signal (PI-2620) to compare people with
Alzheimer’s disease (AD) to healthy individuals. They found higher tau levels
in memory-related brain areas, especially in the medial temporal lobe. This
helped distinguish between healthy and AD groups. A threshold for tau
positivity predicted cognitive problems well in Hispanic and non-Hispanic white
participants, but was less accurate in non-Hispanic Black individuals. Credit:
USC Stevens INI
Tau Cut-Point Shows Limits Across Populations
In this study, researchers compared tau PET scans of
study participants who were cognitively impaired with those who were not
impaired based on cognitive tests to establish a tau cut-point that would
indicate a higher risk for Alzheimer’s disease. They found one, but it was only
effective in certain circumstances.
“Our tau
cut-point was able to distinguish whether study participants had cognitive
impairment – but only when another abnormal protein, amyloid, was also present
in those with cognitive impairment, and only in Hispanic and non-Hispanic White
participants,” said senior author Meredith N. Braskie, PhD, assistant professor
of neurology. “In non-Hispanic Black participants, the tau cut-point did not
perform as expected. This suggests that other pathologies or conditions may be
driving cognitive decline in this group. Our study is an important step toward
better understanding how tau relates to cognition in diverse populations and
has important implications for future clinical trials that aim to target tau.”
18F-PI-2620
Reveals Medial Temporal Threshold
The team used a new imaging tracer, called
18F-PI-2620, to measure tau protein buildup in the brain. They found that when
tau levels in the medial temporal lobe—a region deep in the brain—exceeded a
certain threshold, it strongly indicated cognitive impairment related to AD.
“While our findings support prior research linking medial temporal lobe tau to cognitive impairment, establishing a cut-point in this region using 18F-PI-2620 marks an important step toward defining tau positivity for both research and clinical applications. At the same time, the limited reliability of tau as an indicator of cognitive impairment in non-Hispanic Black participants highlights the need for more diverse populations in research and for future studies to examine both biological and social determinants of Alzheimer’s disease,” said lead author Victoria R. Tennant, a PhD candidate in USC’s Neuroscience Graduate Program.
Toward
Inclusive Alzheimer’s Diagnostics & Care
The findings reflect a growing focus in AD research on
making sure diagnostic tools work for everyone, not just in narrow clinical
trial populations. Alzheimer’s disease is known to affect the brain in stages.
While amyloid plaques often build up early, tau tangles are more closely tied
to memory loss and other symptoms.
“This type of imaging is critical for understanding
who is at risk and how the disease develops,” said Stevens INI director Arthur
W. Toga, PhD. “These findings are just the latest to come from HABS-HD, which
is the most comprehensive study of Alzheimer’s disease and related dementias in
diverse communities. HABS-HD has already produced key findings related to
ethnic variations in AD biomarkers, the influences of social determinants on cognitive
health, and vascular contributions to dementia, just to name a few. We hope
this work will lead to more personalized care and better outcomes for all
communities.”
No comments:
Post a Comment